{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,24]],"date-time":"2026-06-24T04:42:32Z","timestamp":1782276152008,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T00:00:00Z","timestamp":1363219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2013,9]]},"DOI":"10.1038\/jhh.2013.13","type":"journal-article","created":{"date-parts":[[2013,3,14]],"date-time":"2013-03-14T10:22:51Z","timestamp":1363256571000},"page":"535-538","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Aldosterone levels and inflammatory stimulation in essential hypertensive patients"],"prefix":"10.1038","volume":"27","author":[{"given":"V","family":"Tzamou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Vyssoulis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Karpanou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S-M","family":"Kyvelou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T","family":"Gialernios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Stefanadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,3,14]]},"reference":[{"key":"BFjhh201313_CR1","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1097\/01.ASN.0000132473.50966.14","volume":"15","author":"EM Freel","year":"2004","unstructured":"Freel EM, Connell JM . Mechanisms of hypertension: the expanding role of aldosterone. J Am Soc Nephrol 2004; 15: 1993\u20132001.","journal-title":"J Am Soc Nephrol"},{"key":"BFjhh201313_CR2","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1056\/NEJMoa033263","volume":"351","author":"RS Vasan","year":"2004","unstructured":"Vasan RS, Evans JC, Larson MG, Wilson PW, Meigs JB, Rifai N et al. Serum aldosterone and the incidence of hypertension in nonhypertensive persons. N Engl J Med 2004; 351: 33\u201341.","journal-title":"N Engl J Med"},{"key":"BFjhh201313_CR3","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1007\/s11906-006-0059-y","volume":"8","author":"SM Ma ckenzie","year":"2006","unstructured":"Ma ckenzie SM, Connell J . Hypertension and the expanding role of aldosterone. Curr Hypertens Rep 2006; 8: 255\u2013261.","journal-title":"Curr Hypertens Rep"},{"key":"BFjhh201313_CR4","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709\u2013717.","journal-title":"N Engl J Med"},{"key":"BFjhh201313_CR5","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1056\/NEJMoa030207","volume":"348","author":"B Pitt","year":"2003","unstructured":"Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B et al. Eplerenone a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309\u20131321.","journal-title":"N Engl J Med"},{"key":"BFjhh201313_CR6","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1161\/01.ATV.0000181743.28028.57","volume":"25","author":"C De Ciuceis","year":"2005","unstructured":"De Ciuceis C, Amiri F, Brassard P, Endemann DH, Touyz RM, Schiffrin EL . Reduced vascular remodeling, endothelial dysfunction, and oxidative stress inresistance arteries of angiotensin II-infused macrophage colony-stimulatingfactor-deficient mice: evidence for a role in inflammation in angiotensin induced vascular injury. Arterioscler Thromb Vasc Biol 2005; 25: 2106\u20132113.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"BFjhh201313_CR7","first-page":"152","volume":"2","author":"C Savoia","year":"2006","unstructured":"Savoia C, Schiffrin EL . Inflammation in hypertension. Curr Opin Nephrol Hypertens 2006; 2: 152\u2013158.","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"BFjhh201313_CR8","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1042\/CS20060247","volume":"112","author":"C Savoia","year":"2007","unstructured":"Savoia C, Schiffrin EL . Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 2007; 112: 375\u2013384.","journal-title":"Clin Sci (Lond)"},{"key":"BFjhh201313_CR9","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1097\/01.hjh.0000249701.49854.21","volume":"24","author":"P Pietri","year":"2006","unstructured":"Pietri P, Vyssoulis G, Vlachopoulos C, Zervoudaki A, Gialernios T, Aznaouridis K et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006; 24: 2231\u20132238.","journal-title":"J Hypertens"},{"key":"BFjhh201313_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1161\/hh2101.099270","volume":"89","author":"JG Blake","year":"2001","unstructured":"Blake JG, Ridker PM . Novel clinical markers of vascular wall inflammation. Circ Res 2001; 89: 763\u2013771.","journal-title":"Circ Res"},{"key":"BFjhh201313_CR11","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.1001\/jama.290.22.2945","volume":"290","author":"HD Sesso","year":"2003","unstructured":"Sesso HD, Buring JE, Rifai N, Blake GJ, Gaziano JM, Ridker PM . C-reactive protein and the risk of developing hypertension. JAMA 2003; 290: 2945\u20132951.","journal-title":"JAMA"},{"key":"BFjhh201313_CR12","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1161\/01.CIR.0000104566.10178.AF","volume":"108","author":"GJ Blake","year":"2003","unstructured":"Blake GJ, Rifai N, Buring JE, Ridker PM . Blood pressure, C-reactive protein, and risk of future cardiovascular events. Circulation 2003; 108: 2993\u20132999.","journal-title":"Circulation"},{"key":"BFjhh201313_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/01.hjr.0000277984.31558.c4","volume":"2","author":"I Graham","year":"2007","unstructured":"Graham I, Atar D, Borch-Johnsen K, Boysen G, Burell G, Cifkova R et al. European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2007; 2: 1\u201340.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"BFjhh201313_CR14","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1097\/HJH.0b013e3282a9be30","volume":"2510","author":"E Pimenta","year":"2007","unstructured":"Pimenta E, Gaddam KK, Pratt-Ubunama MN, Nishizaka MK, Cofield SS, Oparil S et al. Aldosterone excess and resistance to 24-h blood pressure control. J Hypertens 2007; 2510: 2131\u20132137.","journal-title":"J Hypertens"},{"key":"BFjhh201313_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/MED.0b013e3283391989","volume":"17","author":"KC Gilbert","year":"2010","unstructured":"Gilbert KC, Brown NJ . Aldosterone and inflammation. Curr Opin Endocrinol Diabetes Obes 2010; 17: 199\u201320.","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"BFjhh201313_CR16","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3109\/10641961003628494","volume":"32","author":"M Kurata","year":"2010","unstructured":"Kurata M, Okura T, Irita J, Enomoto D, Nagao T, Jotoku M et al. The relationship between osteopontin and adiponectin in patients with essential hypertension. Clin Exp Hypertens 2010; 32: 358\u2013363.","journal-title":"Clin Exp Hypertens"},{"key":"BFjhh201313_CR17","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1042\/CS20070123","volume":"113","author":"AM Marney","year":"2007","unstructured":"Marney AM, Brown NJ . Aldosterone and end-organ damage. Clin Sci (Lond) 2007; 113: 267\u2013278.","journal-title":"Clin Sci (Lond)"},{"key":"BFjhh201313_CR18","doi-asserted-by":"publisher","first-page":"F1287","DOI":"10.1152\/ajprenal.00017.2008","volume":"294","author":"W Huang","year":"2008","unstructured":"Huang W, Xu C, Kahng KW, Noble NA, Border WA, Huang Y . Aldosterone and TGF-\u03b21 synergistically increase PAI-1 and decrease matrix degradation in rat renal mesangial and fibroblast cells. Am J Physiol Renal Physiol 2008; 294: F1287\u2013F1295.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFjhh201313_CR19","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1038\/ajh.2008.293","volume":"21","author":"LA Sechi","year":"2008","unstructured":"Sechi LA, Novello M, Colussi G, Di Fabio A, Chiuch A, Nadalini E et al. Relationship of plasma renin with aprothrombotic state in hypertension: relevance for organ damage. Am J Hypertens 2008; 21: 1347\u20131353.","journal-title":"Am J Hypertens"},{"key":"BFjhh201313_CR20","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.2215\/CJN.01060306","volume":"1","author":"DA Calhoun","year":"2006","unstructured":"Calhoun DA . Aldosteronism and hypertension. Clin J Am Soc Nephrol 2006; 1: 1039\u20131045.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFjhh201313_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1097\/HJH.0b013e3282f29876","volume":"26","author":"RJ Johnson","year":"2008","unstructured":"Johnson RJ, Feig DI, Nakagawa T, Sanchez-Lozada LG, Rodriguez-Iturbe B . Pathogenesis of essential hypertension: historical paradigms and modern insights. J Hypertens 2008; 26: 381\u2013391.","journal-title":"J Hypertens"},{"key":"BFjhh201313_CR22","doi-asserted-by":"publisher","first-page":"F191","DOI":"10.1152\/ajprenal.0197.2001","volume":"282","author":"B Rodr\u03bdguez-Iturbe","year":"2002","unstructured":"Rodr\u03bdguez-Iturbe B, Quiroz Y, Nava M, Bonet L, Ch\u00e1vez M, Herrera-Acosta J et al. Reduction of renal immune cell infiltration results in blood pressure control in genetically hypertensive rats. Am J Physiol Renal Physiol 2002; 282: F191\u2013F201.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFjhh201313_CR23","doi-asserted-by":"publisher","first-page":"F1132","DOI":"10.1152\/ajprenal.00199.2002","volume":"283","author":"V Alvarez","year":"2002","unstructured":"Alvarez V, Quiroz Y, Nava M, Pons H, Rodr\u03bdguez-Iturbe B . Overload proteinuria is followed by salt-sensitive hypertension caused by renal infiltration of immune cells. Am J Physiol Renal Physiol 2002; 283: F1132\u2013F1141.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFjhh201313_CR24","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/01.HYP.0000075082.06183.4E","volume":"42","author":"J Shao","year":"2003","unstructured":"Shao J, Nangaku M, Miyata T, Inagi R, Yamada K, Kurokawa K et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42: 31\u201338.","journal-title":"Hypertension"},{"key":"BFjhh201313_CR25","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1016\/S0895-7061(98)00099-5","volume":"11","author":"B Kristal","year":"1998","unstructured":"Kristal B, Shurtz-Swirski R, Chezar J, Manaster J, Levy R, Shapiro G et al. Participation of peripheral polymorphonuclear leukocytes in the oxidative stress and inflammation in patients with essential hypertension. Am J Hypertens 1998; 11: 921\u2013928.","journal-title":"Am J Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/jhh201313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201313","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/jhh201313.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,17]],"date-time":"2022-03-17T20:12:33Z","timestamp":1647547953000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/jhh201313"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,3,14]]},"references-count":25,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["BFjhh201313"],"URL":"https:\/\/doi.org\/10.1038\/jhh.2013.13","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"value":"0950-9240","type":"print"},{"value":"1476-5527","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,3,14]]},"assertion":[{"value":"1 February 2012","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2013","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2013","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 March 2013","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}